100% accuracy
of data
of data
24/7 scientific
support
support
0% tolerance in
quality of product
quality of product
Stock Locations
- New Jersey, USA
- Czech Republic, EU
- Mumbai, India
* Stock subject to availability.
Documentation
Includes: HPLC, MASS/LC-MS, 1H NMR, FT-IR, Potency, Structure Elucidation Report (SER), and additional analytical data depending on the product.
153381-68-1Docetaxel EP Impurity C
● In Stock
| Catalogue No.: | VL49002 |
|---|---|
| CAS No.: | 153381-68-1 |
| Mol. Formula: | C43H53NO14 |
| Mol. Weight: | 807.88 g/mol |
Additional information on CAS 153381-68-1
Parent drug
Docetaxel TrihydrateIUPAC Name
(2b, 5b, 7a, 10b, 13a)-4-Acetoxy-13-(((2R, 3S)-3-[(tert-butoxycarbonyl)amino]-2-hydroxy-3-phenylpropanoyl)oxy)-1, 7, 10-trihydroxy-9-oxo-5, 20-epoxytax-11-en-2-yl Benzoate;Synonyms
4-Epidocetaxel / 7-Epi-TaxotereDescription
Docetaxel EP Impurity C (CAS No.: 153381-68-1) or 4-Epidocetaxel is a potent anti-cancer compound and a metabolite of Docetaxel which is an efficacious compound in the treatment of patients with metastatic breast cancer after collapsing of prior chemotherapy. Although docetaxel is accompanied by neutropenia and other adverse effects, it is a well-tolerated and safe medication for breast cancer.References
Mavroudis, D., et al. “Front-Line Treatment of Advanced Breast Cancer with Docetaxel and Epirubicin: A Multicenter Phase II Study.†Annals of Oncology, vol. 11, no. 10, Oct. 2000, pp. 1249–54, https://doi.org/10.1023/a:1008351310818.??Lyseng-Williamson, Katherine A., and Caroline Fenton. “Docetaxel.†Drugs, vol. 65, no. 17, 2005, pp. 2513–31, https://doi.org/10.2165/00003495-200565170-00007.Request a Quote
"*" indicates required fields
Other products related to Docetaxel Trihydrate impurities
Impurity structure
Parent Drug Name
CAS No.
Name of Impurity
Catalog No.
Docetaxel / Docetaxel Trihydrate
CAS No. 148408-66-6
Cat No. VE0027758